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the disease, and have identified choroidal dysfunction as the principal element in CSCR development. New imaging tools have
aided in better monitoring disease response to various treatment models. Enhanced depth imaging optical coherence tomogra-
phy, in particular, has helped in observing choroidal thickness changes after various treatment models. To date, photodynamic
therapy and focal laser remain the main stay of treatment. More understanding of disease pathophysiology in the future will help
in determining the drug of choice and the best management option for such cases.
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Central serous chorioretinopathy (CSCR) is an acquired
chorioretinal disorder that was first described by Von
Graefe in 1866 as recurrent central syphilitic retinitis.1
Other names used to describe this disease entity include
capillarospastic central retinitis, central angiospastic
retinopathy, central serous retinopathy, and central serous
pigment epitheliopathy.2,3
CSCR usually affects middle-aged men between the
ages of twenty and fifty years.4–6 It has also been associ-
ated with type A personality, or those who are experienc-
ing psychological stress.5,7 It has been also linked to use
of sympathomimetic agents, corticosteroid use in any
form, endogenous high levels of corticosteroids, and some
psychopharmacologic agents.8–13 Smokers tend to have
poorer vision and need longer period for visual
rehabilitation.14Clinical features
Patients with CSCR most commonly complain of metamor-
phopsia, micropsia, blurred vision, and mild dyschromatopsia
in the affected eye. On fundus examination, typical signs
include a round well-demarcated detachment of the neu-
rosensory retina at the macula. Pigment epithelial detachment
(PED) of variable size can also occur and can be single or mul-
tiple. The subretinal fluid (SRF) can be clear or turbid/fibri-
nous. The turbid fluid may even form in the sub-retinal
pigment epithelial (sub-RPE) space.15,16 In chronic CSCR or
in patients with old resolved disease, RPE mottling, atrophy,
and clumping might be observed.17–19 In addition, yellow dots
that are thought to represent phagocytosed photoreceptor
outer segments are frequently seen just over the inner surface
of the RPE.18 Other atypical CSCR presentations include bul-
lous neurosensory retinal detachment, inferior neurosensory
detachment with atrophic tracts, and multifocal CSCR.2,20,21e:
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(FA) which may show ‘ink blot’ pattern of leakage or the less
common ‘smoke stack’ appearance that mimics a mushroom
cloud.22 In addition, dye pooling in the sub-RPE space can be
seen in cases of PED. Diffuse leakage or multiple leaking
points can be seen in recurrent, chronic, or multifocal CSCR.
Indocyanine green (ICG) angiography may demonstrate dilat-
ed choroidal vasculature corresponding to the site of CSCR
with choroidal hyperpermeability in the late phase.23,24 Opti-
cal Coherence Tomography (OCT) can demonstrate the neu-
rosensory detachment and areas of PED. Enhanced depth
imaging (EDI) OCT can show the thickened choroid in the
areas corresponding to the neurosensory detachment.25Pathophysiology
Notwithstanding the well-identified clinical picture of
CSCR, its pathophysiology is inadequately understood. Pro-
posed theories include choroidal hyperpermeability which
overloads the RPE pumping mechanism responsible for
keeping the subretinal space dry and may – in some
instances-lead to decompensation and SRF collection.8,26,27
RPE dysfunction is another theory for developing CSCR in
which focal damage of adjacent RPE cells or even a single
RPE cell leads to reversal of ion pumping mechanism and
resulting in fluid accumulation in the subretinal space.28,29
Marmor hypothesized that a dysfunction in the RPE metabol-
ic transport system is needed in order to accumulate subreti-
nal fluid in CSCR due to focal RPE defects.30
An alternative theory is a combined choroidal and RPE
dysfunction.31 In addition, there is a close relationship
between CSCR and both endogenous and exogenous corti-
costeroids suggesting a role in pathogenesis.9–12 It has been
suggested that corticosteroids might sensitize the choroidal
blood vessels or RPE to the effects of catecholamines;32 fur-
thermore, corticosteroids have certain genomic effects on
adrenergic receptor gene transcription and expression which
can result in an increase in the number of adrenergic
receptors.33,34
Zhao et al. were the first to demonstrate that blocking the
aldosterone upregulated the endothelial vasodilatory potas-
sium channels that prevented aldosterone-induced choroidal
thickening. This is suggestive of the presence of mineralocor-
ticoid receptors in the choroidal vasculature which might be
involved in the pathophysiology of CSCR.35Treatment
CSCR is usually a self-limiting disease with spontaneous
resolution within 3–4 months with overall good visual out-
come.36–38 However, recurrences are seen in up to 50% of
patients within the first year.39
Chronic CSCR diseases are the cases in which there are
diffuse RPE changes without evident detachment in most cas-
es.9 However it is sometimes difficult to clinically differentiate
a chronic disease from a recurrent episode of CSCR. Spaide
identified chronic CSCR as serous macular elevation detected
microscopically or by OCT, and is associated with RPE
atrophic areas and subtle leaks or ill-defined staining on
FA.15 These recurrences or chronic neurosensory detach-
ments may lead to RPE atrophy or hypertrophy with irre-
versible loss of visual function.40–44Given all of the above, observation can be regarded as a
first-line approach in newly diagnosed cases of less than
3 month duration.7 In addition, risk factors should be
addressed to increase the chance of spontaneous resolution.
This includes discontinuing exogenous corticosteroids intake
in any form – if possible-, and life style modification for
patients with type A personality traits.7,9,10,45–48 On the other
hand, different modalities of treatment for CSCR exist. These
treatments are reserved for chronic CSCR, recurrent CSCR,
single CSCR attack of more than 3 month duration, and if
the fellow eye suffered from permanent visual loss due to a
previous episode of CSCR whether acute or chronic. We will
discuss below, current, emerging, and advances in therapeu-
tics for CSCR.Laser photocoagulation
Applying laser photocoagulation to the leaking RPE guid-
ed by FA has been shown to hasten resolution of the neu-
rosensory detachment in CSCR. Xenon laser was used at
first followed by krypton laser; currently argon laser is more
widely used.49–51 Many level one evidence studies have
demonstrated faster resolution of SRF in patients who under-
went laser photocoagulation compared to control eyes.52–54
Nevertheless laser photocoagulation does not influence the
final visual outcome or rate of recurrence.6,54,55
Therefore, argon laser photocoagulation is an effective
treatment for acute CSCR with clearly defined focal leakage
point as seen on FA given that the leakage is not subfoveal
or juxtafoveal. Still, side effects such as permanent scotoma,
laser scar enlargement, and laser induced CNV can still occur
(Fig. 1).Micropulse diode laser photocoagulation
This method of treatment uses subthreshold diode laser
energy in order to minimize retinal damage. It is similarly
effective in CSCR with point source leakage but not in eyes
with diffuse leakage, and leaves no clinically detectable
laser-induced damage.56–58 Since there is no visible endpoint
to diode micropulse laser (DMPL) application, ICG enhanced
DMPL can be used to identify treated areas with post-treat-
ment ICG angiography.59
To date, only one randomized clinical trial (RCT) assessed
DMPL versus argon laser photocoagulation in acute CSCR.60
Patients in both groups had complete resolution of SRF at
12 weeks of follow-up. All patients had no scotomas in the
DMPL group compared to 3 out of 15 patients in the argon
laser group who had persistent scotomas. Contrast sensitivity
was also significantly better in the DMPL group.60Transpupillary thermotherapy
Transpupillary thermotherapy (TTT) is a 810 nm long-pulse
low-energy diode laser. It works by raising the temperature
of the choroid and outer retina while sparing the inner retina
and photoreceptors to some degree, but the exact mechan-
ism is not clear.61 First described in 2005 by Wei, short-term
encouraging visual and anatomical outcomes have been
observed in CSCR with subfoveal leaks, multiple or diffuse
leaks, and recurrent atypical CSCR with PEDs.61–64 More well
structured RCTs with long-term results are required to estab-
lish the role of TTT in the treatment of CSCR.
Figure 1. Left eye of a 32-year-old man with chronic CSCR showing turbid subretinal fluid (top right). Fluorescein angiography shows pin-point leakage
between the optic nerve and fovea (top left). Six months after focal laser photocoagulation to the leakage site shows resolution of the subretinal fluid
with enlargement of the laser scar and some atrophic RPE changes (bottom right). Fluorescein angiography shows hypofluorescent area surrounded by a
hyperfluorescent rim corresponding to the laser scar (bottom left). (Courtesy of Dr. Saba Al-Rashaed).
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Photodynamic therapy (PDT) with verteporfin has been
employed to treat both chronic and acute CSCR, as well as,
to reduce recurrences. It is believed that PDT works in CSCR
by inducing choroidal hypoperfusion, and vascular narrowing
and remodeling to negate choroidal hyperpermeability which
is consistently found in CSCR cases.65,66 Others have pro-
posed that PDT can also tighten the blood retina barrier.67
Standard PDT
Chan et al. reported the first case series of full dose, full
fluence PDT in 6 patients with persistent or chronic CSCR
with subfoveal leakage.68 Many RCTs demonstrated the effi-
cacy of PDT. Inoue et al. reported that PDT is not effective or
recurrence rate is thought to be high in eyes with no intense
hyperfluorescence on ICG.69 Moon et al. concluded that visu-
al recovery might be limited in CSCR patients with lengthy
symptom duration, post-PDT RPE atrophy progression, and
in patients with possible foveal injury from PDT.70 Tsakonas
and coworkers demonstrated the effectiveness and safety
of FA-guided full fluence PDT using multiple PDT spots at
the same session for chronic CSCR.71 Thus even FA-guided
PDT can be an effective alternative in cases where ICG is
not available.
Ruiz-Moreno treated 82 eyes with standard PDT for chron-
ic CSCR and showed that it can improve visual acuity and
reduce central macular thickness (CMT). SRF has disappeared
in all cases. In his large case series, no patient developed sev-
ere visual loss or complications derived from PDT with an
average follow-up of 12 months. However, 9 cases devel-
oped reactive RPE hypertrophy after PDT.72 Furthermore,
neuroretinal thinning after standard PDT has been described,
but is not correlated with visual acuity decrease.73,74 Morpho-
logical and functional chorioretinal changes such as RPEatrophy, external limiting membrane and inner segment/
outer segment junction line discontinuity have been
observed after standard PDT treatment for CSCR, but were
not correlated with the area of PDT treatment nor with the
change in visual acuity.74 These post-PDT changes probably
represent accelerated course of the disease, which if left to
its natural chronic course might cause more damage.
Due to possible treatment-related risks such as choroidal
ischemia, RPE atrophy, RPE rip, and secondary choroidal
neovascular membrane (CNVM), some safety measures were
adopted in order to minimize these risks.68,75–78 These safety-
enhanced measures include reducing the dose or power (flu-
ence) of PDT (Figs. 2 and 3).
Reduced dose PDT
A short-term pilot study by Lai et al. using half dose verte-
porfin for chronic CSCR has demonstrated both efficacy and
safety.77 Chan et al. have shown in an RCT that included 63
patients that half dose PDT was also effective both
anatomically and functionally in treating acute symptomatic
CSCR.65 A comparative case series by Lim et al. have shown
that half dose PDT facilitated earlier resolution of SRF and
earlier recovery of visual function when compared to focal
laser. No difference in final functional and anatomical results
was noted at six month follow-up.79 Kim and coworkers used
FA-guided half dose PDT for acute CSCR and found that
long-term anatomic and functional outcomes were not con-
vincing when compared to observation only at the end of
one year of follow-up in spite of complete resolution of SRF
in 100% of cases at the 3 month follow-up point.80
Maruko et al. found that subfoveal choroidal thickness and
ICG hyperpermeability decreased after PDT compared to
laser photocoagulation.81 Ratanasukon et al. concluded that
about 45% of CSCR patients treated with half dose PDT
had photoreceptor disruption at 1-year follow-up that
Figure 2. Left eye of a 48-year-old man with recurrent CSCR who was misdiagnosed as wet macular degeneration. Note the dull foveal reflex and RPE
atrophic changes (top right). Fluorescein angiography shows diffuse irregular hyperfluorescence (top left). Optical coherence tomography shows shallow
subretinal fluid reaching the fovea (Down).
Figure 3. Indocyanine green of the previous patient in Fig. 2 shows dilated/engorged choroidal vessels corresponding to the leakage seen on
fluorescein angiography (top right). Late phase shows leakage from these choroidal vessels (top left). One month after half-dose photodynamic therapy
the hypocyanescent area corresponds to the site of treatment (bottom right). It shows overall reduction in vascularity with decrease in choroidal vessel
caliber. No more leakage can be seen on late phase of ICG (bottom left).
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however, that the photoreceptor line at baseline was difficult
to identify and that only the final photoreceptor status was
documented but was not compared to baseline photorecep-
tor status.82 Karakus et al. showed that half dose PDT was
effective and safe after up to 3 years of follow-up for chronicCSCR with improvement in contrast sensitivity compared to
baseline.83
Dang et al. studied subfoveal choroidal thickness after
one-third PDT dose, and found that subfoveal choroid was
thicker in patients with acute CSCR than in normal population
with symptomatic eyes being significantly thicker than in fel-
282 M.A. Abouammohlow eyes.84 Zhao proposed that the lowest safe effective
dose of verteporfin was 30% of the standard dose in treating
acute CSCR.85 Uetani and colleagues showed that half dose
PDT was more effective than one-third PDT dose for chronic
CSCR.86 Nicolo concluded that chronic CSCR with posterior
retinal cystoid degeneration might do worse when treated
with half dose PDT when compared to chronic CSCR with
SRF alone.87Reduced fluence PDT
As some of the risks of PDT still exist after reducing the
dose of verteporfin, reducing the fluence by decreasing laser
time or power was attempted. Reibaldi et al. compared full
fluence to half fluence PDT in chronic CSCR. Both treatments
achieved similar results in terms of visual outcome and SRF
resolution, but choriocapillaris ischemia was significantly
more in the full fluence group.76 Similar promising results
for reduced fluence PDT in terms of safety and efficacy have
also been documented with half fluence and even minimal
(12 J/cm2) fluence.88–91
Ohkuma et al. concluded that the outer nuclear layer
thickness is a significant predictive factor for visual acuity
after reduced fluence PDT for CSCR at 1 year.92 Kang
et al. showed that subfoveal choroidal thickness decreased
after reduced fluence PDT, as well as, after spontaneous
resolution, but normal subfoveal thickness was only
achieved in the PDT group.93 Nicolo compared half-fluence
to half-dose PDT for chronic CSCR, and found that half-dose
PDT induced faster SRF resolution and that the effects seem
to last longer than half-fluence PDT. However, both were
equally safe.94
Larger RCTs with long-term follow-up are still needed to
establish the most effective and safe way for treating CSCR
using PDT. The ideal PDT treatment for CSCR would be that
which achieves the best results with the least possible
complications.Intravitreal antivascular endothelial growth factor
(VEGF)
Attempts to treat acute and chronic CSCR with intravitre-
al bevacizumab are based on the hypothesis that choroidal
hyperpermeability is associated with increased expression of
VEGF, albeit high VEGF levels were not detected in the
aqueous humor.95–98 Yet, Jung et al. have demonstrated
that CSCR patients who responded to intravitreal beva-
cizumab had higher aqueous levels than those who did
not respond.99
Lim et al. reported the absence of any positive effect in a
series of 12 patients treated with a single intravitreal beva-
cizumab injection (1.25 mg/0.05 ml) when compared to
observation group (12 eyes) during a six-month follow-up.
Bae et al. demonstrated in another RCT that reduced-fluence
PDT was superior to 3 monthly doses of intravitreal
ranibizumab. They found that over 1-year of follow-up, 16
eyes (89%) remained dry in the PDT group versus only 2 eyes
(12.5%) in the ranibizumab group. Visual acuity improved in
both groups, but the difference was significantly better in
the PDT group at the 3-month time point.100
Other uncontrolled case series suggest efficacy of anti-
VEGF intravitreal injections for CSCR both functionally and
anatomically.95,101–107 As the natural history of CSCR is gen-erally favorable, the lack of controls in these case series, is
noteworthy. On the other hand, anti-VEGF therapy has a
much obvious, well-established role in CNVMs secondary to
CSCR.108,109Anti-corticosteroids
The connotation of corticosteroid use and the develop-
ment of CSCR have led to the suggestion of anti-corticos-
teroids as a treatment.32 This has led to several clinical
trials to assess the effect of such treatment.
Ketoconazole is a synthetic imidazole which, in addition
to its anti-fungal properties, has anti-glucocorticoid effects
by blocking the conversion of cholesterol to androgenic glu-
cocorticoid end-products. Meyerle et al. did not note any
change in visual acuity, median lesion height on OCT, and
linear dimensions through an 8-week follow-up period for
5 chronic CSCR patients who received oral ketoconazole
600 mg per day for 4 weeks in spite of documented
decrease in endogenous cortisol levels.110 Golshahi in a
comparative non-randomized study of 15 patients with
acute CSCR treated with ketoconazole for 4 weeks versus
15 patients in the control group concluded that systemic
ketoconazole was not associated with a significantly better
outcome.111
Mifepristone (RU-486) is an abortifacient agent. Its
mechanism of action is mediated through its glucocorticoid
and progesterone receptor antagonistic effects. Nielsen
et al. studied 16 patients with chronic CSCR in an uncon-
trolled study. Systemic mifepristone 200 mg was adminis-
tered for up to 12 weeks. Seven patients gained P5 letters
of vision, and 7 patients had improved OCT findings. This
led to the conclusion that oral mifepristone has a beneficial
effect in some CSCR cases.112
Spironolactone and eplerenone are both aldosterone
antagonist agents. Spironolactone possesses additional
anti-androgen properties. Few case-series documented a
reduction or complete resolution of SRF level and significant
CMT reduction.113–116 However, RCTs are warranted to fur-
ther clarify the role of aldosterone receptor antagonist in
CSCR. Currently there is only one ongoing trial with eplere-
none (Clinical trial: NCT01990677).
Rifampicin is an anti-tuberculous medication which is
thought to facilitate catabolism of endogenous steroids. It
causes a proliferation of the smooth endoplasmic reticulum
and an increase in the cytochrome P-450 content in the liver,
thus affecting the metabolism and bioavailability of endoge-
nous corticosteroids, consequently aiding in resolution of
CSCR and improving its symptomatology.117,118 However,
care is to be taken as hepatotoxicity can develop as a side
effect while being treated for CSCR.119
Finasteride is a weak anti-androgen that worked mainly
through inhibiting type II 5 a-reductase that is necessary for
converting testosterone to dihydrotestosterone (DHT), a
potent androgen. Forooghian et al. described 5 cases of
chronic CSCR treated with oral finasteride 5 mg daily for
3 months. Mean CMT and SRF volume decreased in all
patients. This reduction corresponded to a drop in DHT
serum levels in all patients. Following the cessation of finas-
teride, all patients but one had SRF recollection and an
increase in CMT.120 More trials are needed to evaluate the
effect of finasteride in CSCR.
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As CSCR is closely associated with type A personality
which is characterized by high adrenergic activity, it was pro-
posed that blocking adrenergic receptors might have a posi-
tive effect on CSCR.121 It has been shown that CSCR patients
who were diagnosed to have hypertension and were started
on metoprolol – a beta blocker – had improved symptoma-
tology. Recurrence of CSCR once metoprolol was stopped
was also noticed.122 Chrapek et al. demonstrated no effect
of metipranolol on acute CSCR in a recent double-blinded
RCT in which 23 patients received 10 mg of metipranolol
for up to 45 weeks compared to placebo pills in 25
patients.123 The contradictory results demand further assess-
ment of the actual role of adrenergic blockers.
Systemic carbonic anhydrase inhibitors (CAIs)
CAIs are thought to mediate its action by inhibiting car-
bonic anhydrase enzyme in RPE, which supposedly aid in
SRF absorption. Pikkel et al. reported a prospective non-ran-
domized trial on 15 CAI-treated patients against 7 controls.
They found that oral acetazolamide shortens the time for
subjective and clinical improvement, but there was no differ-
ence in final visual acuity or recurrence rate between the two
groups.124
Aspirin
Caccavale et al. compared 109 patients with CSCR, who
were treated with aspirin 100 mg once a day for a month fol-
lowed by 100 mg every other day for 5 months, to a historic
control group of 89 patients. They concluded that treatment
with aspirin may hasten visual improvement and reduce
recurrences compared to no treatment.125,126 They theorized
that the CSCR is due to impaired fibrinolysis and increased
platelet aggregation in the choriocapillaris.125 Therefore, it
is presumed that aspirin works in such cases through its fibri-
nolytic and anti-platelet action.
Helicobacter pylori treatment
H. Pylori infection has been recently linked to CSCR.127,128
Rahbani-Nobar showed on a non-randomized trial the effica-
cy of anti-H. Pylori treatment regimen in hastening the
absorption of SRF.129 A RCT by Dang et al. concluded that
anti-H. Pylori treatment regimen does not improve vision,
SRF, nor alter the clinical course.130 The exact role of anti-
H. Pylori treatment in the management of CSCR remains to
be defined.
Methotrexate
Methotrexate is an antimetabolite drug that basically inhi-
bits folic acid metabolism. It is used successfully for treating
certain cancer entities, and some autoimmune rheumatologic
diseases, including certain forms of vasculitis. Kurup et al. ret-
rospectively evaluated methotrexate as a treatment for
chronic CSCR in 11 eyes. They found that the mean CMT
and visual acuity improved significantly compared to baseline
values, and 9 eyes (83%) remained dry after completion of
the treatment regimen. The mean duration of treatmentwas 12 weeks.131 More trials are needed to explore the
potentials of methotrexate in treating CSCR and understand
its mechanism of action.
Search strategy
This review was conducted by performing an electronic
search of the Medline and EMBASE databases. The search
was limited to English language, and humans. We searched
the databases for relevant terms which included central ser-
ous retinopathy, central serous chorioretinopathy, photody-
namic therapy, CSC, CSCR, and treatment of central serous
chorioretinopathy. In addition, referenced articles from
extracted research papers were also reviewed for additional
data and the articles were retrieved if deemed relevant.
Conclusion
CSCR is a multifactorial disease that remains incompletely
understood. Recent imaging innovations have led to further
understanding and better monitoring of disease progression
and response to treatment. The gold standard of care for
CSCR is yet to be defined. To date, PDT offers good clinical
results that are maintained for an extended period of time.
Further long-term trials and continuous advances in retinal
therapeutics might culminate in achieving the drug of choice
for CSCR.
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